Myriad Genetics Stock Price, News & Analysis

Myriad Genetics (NASDAQ: MYGN) has secured a new $200 million credit facility from OrbiMed, a leading healthcare investment firm. The five-year senior secured term loan includes $125 million in immediate funded capital and an option for an additional $75 million available until June 30, 2027.

The facility matures on July 31, 2030, with an interest rate based on one-month SOFR plus 6.50% annually (SOFR floor of 2.50%). This new arrangement replaces Myriad's previous ABL facility and is secured by substantially all company assets. The funding strengthens Myriad's capital position, providing over $200 million in accessible capital to support its growth strategy.

Myriad Genetics (NASDAQ: MYGN), a molecular diagnostic testing and precision medicine company, has scheduled its second quarter 2025 earnings release and conference call for August 5, 2025. The financial results will be released after market close, followed by a conference call at 4:30 PM ET.

Management will discuss the company's Q2 2025 financial performance and provide a business update during the call. Investors can access the live webcast through Myriad's Investor Relations website, while those preferring telephone participation must register to receive dial-in details.

Myriad Genetics (NASDAQ: MYGN) has achieved Great Place to Work Certification for the third consecutive year, with 84% of employees endorsing the company as a great workplace - surpassing the U.S. company average by 30 percentage points.

The certification, granted by Great Place To Work®, the global authority on workplace culture, recognizes Myriad's commitment to creating an inclusive and supportive work environment. The company's success is attributed to its focus on employee resource groups, community building, and ensuring teammates feel connected and empowered.

Myriad Genetics (NASDAQ: MYGN) has announced early access to its FirstGene Multiple Prenatal Screen, a comprehensive prenatal genetic testing solution. The test combines multiple screening modalities into a single blood draw, eliminating the need for paternal testing. FirstGene will be launched through the CONNECTOR study, targeting over 5,000 patients across multiple clinical sites. The screen offers high accuracy with 98.6% sensitivity and 99.6% specificity, capable of identifying carrier status, fetal genetic anomalies, chromosomal aneuploidies, 22q11.2 microdeletion, pathogenic mutations in 10 recessive conditions, and RhD compatibility. This streamlined approach makes guideline-driven testing more accessible while representing a significant growth opportunity for Myriad in the prenatal testing market.

Myriad Genetics (MYGN) revealed promising clinical data from the MONSTAR-SCREEN-3 study for their Precise MRD Test, demonstrating 100% detection of circulating tumor DNA (ctDNA) at baseline across multiple cancer types. The study, conducted with Japan's National Cancer Center Hospital East, showed the test can detect tumor fractions as low as 0.0001% and successfully created personalized whole-genome sequencing panels for 97.3% of patients. Notably, 60% of ctDNA-positive patients one month post-surgery had ultra-low tumor fractions only detectable by Precise MRD's enhanced sensitivity. These patients showed significantly worse disease-free survival compared to ctDNA-negative patients. The test also demonstrated ability to predict pathological complete response during neoadjuvant chemotherapy and showed earlier recurrence detection compared to imaging.

Myriad Genetics (NASDAQ: MYGN) will present seven new research studies at the 2025 ASCO Annual Meeting, showcasing advancements in oncology and precision medicine. Key highlights include the MONSTAR-SCREEN-3 study, demonstrating successful pan-cancer implementation of whole genome sequencing-based personalized ctDNA detection, achieving 100% baseline detection across tumor types. The company announced upcoming product innovations including: Precise MRD Test (commercial launch in 2026), Prolaris Prostate Cancer Test with PATHOMIQ AI technology (early 2026), expanded MyRisk Hereditary Cancer Test panel (late 2025), and full EMR integration with Flatiron's OncoEMR and Epic platforms (late 2025). These developments reflect Myriad's commitment to advancing personalized cancer care through genetic and tumor genomic testing solutions.

Myriad Genetics (NASDAQ: MYGN), a molecular diagnostic testing and precision medicine company, has announced its participation in two major upcoming healthcare investor conferences. Management will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 6:00 PM ET, and at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, at 2:00 PM ET. Both presentations will be available for viewing through live and archived webcasts on the company's investor relations website at investor.myriad.com.

Myriad Genetics (NASDAQ: MYGN) announced the publication of a real-world study in JCO Precision Oncology demonstrating the effectiveness of their RiskScore® breast cancer risk assessment tool. The study showed that RiskScore predicted different risk levels than the Tyrer-Cuzick model for nearly 20% of patients. Notably, patients with ≥20% lifetime breast cancer risk identified by RiskScore were more likely to receive guidelines-aligned screening, including mammography, breast MRI, and genetic counseling.

RiskScore, which is integrated into Myriad's MyRisk® Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick model to predict five-year and remaining lifetime breast cancer risk. The study findings suggest that clinicians are effectively utilizing RiskScore results to make informed decisions about patient risk management and screening recommendations.

Myriad Genetics (MYGN) reported challenging Q1 2025 results with revenue of $196 million, declining 3% year-over-year. Excluding $16M in headwinds, revenue grew 5%. The company's Prenatal segment showed 11% growth, while Pharmacogenomics revenue dropped 20% due to UnitedHealthcare reducing GeneSight® coverage. Test volumes reached 385,000, up 1% YoY. The company reported a minimal GAAP net loss of $0.1M ($0.00 EPS) and adjusted EPS of $(0.03). Myriad updated its 2025 guidance, lowering revenue expectations to $807-823 million from $840-860 million, and adjusted EPS to $(0.02)-$0.02 from $0.07-$0.11. The company maintains a strong liquidity position with $92 million in cash and access to an additional $42 million through its credit facility.